Akzo Nobel announces further approval for OBS sale

Amsterdam, the Netherlands, November 16, 2007 - Schering-Plough Corporation has received antitrust clearance from the U.S. Federal Trade Commission (FTC) regarding its planned acquisition of Organon BioSciences N.V. (OBS) from Akzo Nobel N.V. In connection with the conditional FTC clearance, Schering-Plough and the OBS animal health business, Intervet, will divest three poultry vaccines in the United States. No divestitures of human health products are required. The EUR 11 billion deal was announced in March and Schering-Plough has already received approval for the transaction from the European Commission. Akzo Nobel and Schering-Plough continue to expect the deal to be completed by the end of 2007. - - - Note to editors Akzo Nobel is a Fortune Global 500 company and is listed on Euronext Amsterdam. It is also the Chemicals Industry leader on the Dow Jones Sustainability Indexes and Akzo Nobel is included on the FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with coatings, chemicals and human and animal healthcare products. We employ around 62,000 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the year 2007 will be published on March 6, 2008. Internet: www.akzonobel.com Not for publication - for more information Akzo Nobel N.V. Corporate Media Relations, tel. +31 20 502 7833 Contact: Marc Michelsen